You're not logged in. Please log in to earn stock or Bitcoin rewards on your prescription purchase.
Syfovre
Syfovre (generic name: pegcetacoplan) is an injectable medication used for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). GA leads to the progressive and irreversible loss of photoreceptors and retinal pigment epithelium (RPE), leading to central vision loss. Syfovre works by inhibiting C3 complement protein, which plays a role in the inflammation and immune responses that contribute to the progression of GA.
Oops! We currently don’t have the pricing information for this drug.
But we're continually improving our service to help you save and earn rebates on your medications. If your drug isn't listed on NiHowdy, you can still present your NiHowdy savings card at the pharmacy. We'll work to secure any eligible rebates for that drug and pass the savings back to you retroactively.
Members have saved
$NaN
using our savings card for instant savings.
Don't pay full retail price and miss out on potential savings. Try it now—you have nothing to lose!
NaNM
worth of Satoshi has been rewarded to our members.
Everyone who signs up enjoys the benefits of earning FREE Bitcoin with every purchase.
Frequently Asked Questions
How long does it take for Syfovre to work?
Syfovre is designed to slow the progression of geographic atrophy, but results may take several months. Continued treatment is necessary to maintain its effects.
Can I receive Syfovre if I have an eye infection?
No, if you have an active ocular or periocular infection, treatment with Syfovre should be delayed until the infection resolves.
What should I do if I experience eye pain after the injection?
If you experience severe eye pain, vision changes, or symptoms like flashes of light or floaters after receiving Syfovre, contact your ophthalmologist immediately, as these could be signs of complications such as endophthalmitis or retinal detachment.
How often will I need to receive Syfovre injections?
Syfovre is typically administered once every 25 to 60 days, depending on your specific condition and how your disease is progressing.
Can Syfovre reverse geographic atrophy?
Syfovre does not reverse geographic atrophy but is designed to slow the progression of the disease. Regular treatment is required to maintain its benefits.
Comprehensive Drug Guide
How Does Syfovre Work?
Syfovre works by inhibiting C3 complement protein, a key component of the complement system involved in immune response and inflammation. By targeting C3, Syfovre reduces the overactivation of the complement pathway, which is thought to contribute to the progression of geographic atrophy in patients with age-related macular degeneration.
Common Dosages
- 15 mg/0.1 mL injected into the affected eye once every 25 to 60 days (approximately every 4 to 8 weeks), depending on the patient’s specific treatment plan.
Typical Dosing
- The typical dose is 15 mg administered by intravitreal injection once every 25 to 60 days, based on the patient's condition and the treating physician’s recommendation.
Typical Dosing
FDA Approved Indications
- Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in adults.
Who Shouldn't Take Syfovre?
- Ocular or periocular infections: Syfovre should not be administered in patients with active infections in or around the eyes.
- Known hypersensitivity to pegcetacoplan or any of the components in Syfovre.
Advice From The Pharmacist
- Syfovre is administered by a healthcare provider: It is injected directly into the eye by an ophthalmologist.
- Report any vision changes or eye discomfort to your healthcare provider after receiving Syfovre, as these could indicate complications.
- Follow-up is crucial: Regular monitoring and injections every 25 to 60 days are needed for continued control of the disease progression.
Side Effects of Syfovre
Common Side Effects
- Eye pain
- Vitreous floaters
- Increased intraocular pressure
- Blurred vision
Uncommon/Severe Side Effects
- Endophthalmitis (infection inside the eye)
- Retinal detachment
- Severe intraocular inflammation
Risks and Warnings of Syfovre
- Endophthalmitis Risk: Intravitreal injections carry the risk of endophthalmitis, a severe eye infection. Patients should be monitored closely for signs of infection, including increased redness, pain, or decreased vision after injection.
- Retinal Detachment: There is a risk of retinal detachment associated with intravitreal injections. Symptoms such as flashes of light, floaters, or sudden vision loss should be reported immediately.
- Increased Intraocular Pressure: Injections into the eye can cause a temporary increase in intraocular pressure, which should be monitored by your ophthalmologist.
Interactions with Syfovre
Common Drug Interactions
- Other intravitreal medications: If other intravitreal injections or eye medications are being used, inform your healthcare provider to ensure there are no adverse interactions.
- Anticoagulants or blood thinners: If you are on anticoagulant therapy, there may be an increased risk of bleeding at the injection site, so your healthcare provider may monitor you more closely.
Alternatives to Syfovre
- Aflibercept (Eylea): An anti-VEGF medication used to treat age-related macular degeneration (wet form) but not specifically approved for geographic atrophy.
- Ranibizumab (Lucentis): Another anti-VEGF medication used for macular degeneration, although primarily for the wet form of AMD.
- Lampalizumab: A complement inhibitor that has been studied for geographic atrophy, although it is not currently approved for this indication.
